• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Choroidal Response to Anti-VEGF Therapy in Subgroups Classified by Preexisting Ophthalmic or Systemic Condition.

作者信息

Ahn Seong Joon, Park Kyu Hyung, Woo Se Joon

机构信息

Department of Ophthalmology Seoul National University Bundang Hospital, Seongnam, South Korea 2Department of Ophthalmology, Hanyang University Hospital, Seoul, South Korea.

Department of Ophthalmology Seoul National University Bundang Hospital, Seongnam, South Korea.

出版信息

Invest Ophthalmol Vis Sci. 2015 Dec;56(13):8364. doi: 10.1167/iovs.15-18634.

DOI:10.1167/iovs.15-18634
PMID:26747766
Abstract
摘要

相似文献

1
Choroidal Response to Anti-VEGF Therapy in Subgroups Classified by Preexisting Ophthalmic or Systemic Condition.根据既往眼科或全身疾病分类的亚组中脉络膜对抗血管内皮生长因子(VEGF)治疗的反应
Invest Ophthalmol Vis Sci. 2015 Dec;56(13):8364. doi: 10.1167/iovs.15-18634.
2
Tailoring Myopic CNV Treatment Based on Preexisting Ophthalmic Condition.
Invest Ophthalmol Vis Sci. 2015 Dec;56(13):8362-3. doi: 10.1167/iovs.15-18314.
3
Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.近视性脉络膜新生血管抗血管内皮生长因子治疗后黄斑中心凹下脉络膜厚度变化
Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5794-800. doi: 10.1167/iovs.14-16006.
4
The role of anti-VEGF agents in myopic choroidal neovascularization: Current standards and future outlook.抗血管内皮生长因子药物在近视性脉络膜新生血管中的作用:当前标准与未来展望。
Expert Opin Biol Ther. 2016;16(4):477-87. doi: 10.1517/14712598.2016.1132696. Epub 2016 Feb 12.
5
[Research progress of treatment strategies for choroidal neovascularization secondary to pathological myopia].
Zhonghua Yan Ke Za Zhi. 2019 Oct 11;55(10):791-795. doi: 10.3760/cma.j.issn.0412-4081.2019.10.013.
6
A new treatment algorithm for the management of myopic choroidal neovascularization using intravitreal ranibizumab.一种使用玻璃体内注射雷珠单抗治疗近视性脉络膜新生血管的新治疗方案。
Acta Ophthalmol. 2015 Sep;93(6):e519-20. doi: 10.1111/aos.12677. Epub 2015 Apr 1.
7
A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.玻璃体内注射贝伐单抗与雷珠单抗治疗近视性脉络膜新生血管的随机试验。
Graefes Arch Clin Exp Ophthalmol. 2015 Nov;253(11):1867-72. doi: 10.1007/s00417-014-2886-x. Epub 2014 Dec 13.
8
Distribution of recurrence time intervals after anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization.抗血管内皮生长因子治疗近视性脉络膜新生血管后复发时间间隔的分布情况。
Can J Ophthalmol. 2021 Apr;56(2):137-138. doi: 10.1016/j.jcjo.2020.08.004. Epub 2020 Sep 10.
9
Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab.治疗性单克隆抗体及其片段:雷珠单抗。
Dev Ophthalmol. 2016;55:246-51. doi: 10.1159/000431200. Epub 2015 Oct 26.
10
Concurrent management of myopic choroidal neovascularization and rhegmatogenous retinal detachment with intravitreal antivascular endothelial growth factor during primary retinal detachment repair.在原发性视网膜脱离修复过程中,眼内注射抗血管内皮生长因子同时治疗近视性脉络膜新生血管和孔源性视网膜脱离。
Indian J Ophthalmol. 2018 Mar;66(3):472-474. doi: 10.4103/ijo.IJO_856_17.